Page results
-
Our annual members' meeting (AMM) brings together members, governors and staff, and is where our governors officially receive our annual report and accounts.
-
Advice on socialising and managing friendships for young people living with fatigue conditions.
-
Once again, UCLH has received the highest score of all general acute and acute/community NHS trusts in England for staff that would recommend us as a place to work
-
This page explains what an intra-oral scanner is and what it is used for.
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy).
-
An online talk about being active. The talk is for people who have recently finished cancer treatment at UCLH
-
Here you find all of our information leaflets which will help with day to day diabetes management including managing highs and lows, sick day rules and managing school days including the most up to date school care plans. You will also find information on how to upload your devices at home.
-
UCLH Phlebotomy department is introducing Swiftqueue - an appointment system that enables patients, and GPs who refer patients, to book UCLH blood test appointments online.
-
UCLH clinical trial practitioner Antonette Andrews was amazed to learn that her great aunt came to the UK as part of the Windrush Generation and joined the NHS, where Antonette works today.
File results
-
FOI/2022/0544 - Wards/ departments that provide services to 0-17 year-olds
-
FOI/2022/0545 - Criteria used in determining acceptance of GP referrals for osteoporosis treatment, and for priorisation of osteoporosis appointments
-
FOI/2022/0546 - Metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology
-
FOI/2022/0549 - SACT (systemic anti-cancer therapy) /cervical cancer treatments
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis